Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 20/20 | 0.64 |
| ▸ | CX3CR1 | P49238 | 16/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4115274 | 1.00 | CXCR2 (0.64) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL4128377 | 0.91 | CXCR2 (0.72) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL4128383 | 0.91 | CXCR2 (0.72) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL4059548 | 0.87 | CXCR2 (0.59) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL4059541 | 0.87 | CXCR2 (0.59) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL212653 | 0.86 | CXCR2 (0.81) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL4055134 | 0.85 | CXCR2 (0.71) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL4055126 | 0.85 | CXCR2 (0.71) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL1854880 | 0.83 | CXCR2 (0.73) | CXCR2CX3CR1ADORA1 | |
| SCHEMBL9108160 | 0.80 | CXCR2 (0.78) | CXCR2CX3CR1ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009120140-A1 | NOVEL 5,7-DISUBSTITUTED [1,3]THIAZOLO[4,5-D]PYRIMIDIN-2(3H)-ONE DERIVATIVES 258 | ASTRAZENECA AB (SE) | 2009-10-01 | — | — | WO | claimed |
| US-20090247555-A1 | 5,7-Disubstituted[1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 258 | ASTRAZENECA AB (SE) | 2009-10-01 | — | — | US | claimed |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2019-09-17 | — | — | US | disclosed |
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2018-04-12 | — | — | US | disclosed |
| US-9856260-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | UNIV DREXEL (US) | 2016-09-15 | — | — | US | disclosed |
| US-9375474-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | DREXEL UNIVERSITY (US) | 2016-06-28 | — | — | US | disclosed |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | Alliance Discovery, Inc. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8435993-B2 | Methods of inhibiting metastasis from cancer | PHILADELPHIA HEALTH AND EDUCATION CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | Alliance Discovery, Inc. | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099972-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CXCR2 7/4885CX3CR1 1/4885ADORA1 368/4885 |
| US-10414771-B2 | Compounds useful for inhibiting metastasis from cancer and methods using same | CX3CR1, CCL2, CCR5 | CXCR2 7/4885CX3CR1 1/4885ADORA1 368/4885 |
| US-20090247555-A1 | 5,7-Disubstituted[1,3]Thiazolo[4,5-D]Pyrimidin-2(3H)-One Derivatives 258 | CX3CR1, CCR2, CXCR3 | CXCR2 7/4885CX3CR1 1/4885ADORA1 119/4885 |
| US-20120141471-A1 | Methods of Inhibiting Metastasis from Cancer | CX3CR1, CXCR3, CCR5 | CXCR2 7/4885CX3CR1 1/4885ADORA1 336/4885 |
| US-20130156761-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CXCR2 7/4885CX3CR1 1/4885ADORA1 368/4885 |
| US-20160264587-A1 | Compounds Useful for Inhibiting Metastasis from Cancer and Methods Using Same | CX3CR1, CCL2, CCR5 | CXCR2 7/4885CX3CR1 1/4885ADORA1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.